Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. Earlier stage biotechs are trying to turn their platforms into research revenue as they look to non-profit, government, and private funding sources to advance their preclinical therapeutic programs. Whatever the model, worries abound that the financial woes of the next couple of years could blunt hard-earned momentum.
Two words help explain why researchers, clinicians and patients with life-threatening disease hold so much hope for regenerative medicine: Berlin Man.
That's the moniker for the anonymous leukemia patient who underwent a bone marrow transplant treatment at the Charite Clinic in Berlin nearly three years ago. He was also HIV-positive, and doctors decided to match him with a donor whose T cells had a rare mutation of the CCR5 receptor known as Delta 32 that confers HIV resistance
Vyepti revenues rise by nearly 70% in the first quarter.
As CEO Anderson backs high prices for innovative drugs in Europe
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
